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Joint Commission on Accreditation of
Healthcare Organizations’
2006 National Patient Safety Goals
By: Kristen Garris, PharmD
Pharmacy Practice Resident
The purpose of the Joint
Commission on Accreditation
of
Healthcare
Organizations’ (JCAHO) National Patient
Safety Goals (NPSGs) is to promote specific improvements in
patient safety. NPSGs focus on
problematic areas in health care
and describe evidence- and expert-based solutions to these
problems. Recognizing that
sound system design is intrinsic
to the delivery of safe, high quality health care, NPSGs focus on
system-wide solutions, wherever
possible.
NPSGs are derived primarily
from informal recommendations
made in the JCAHO safety
newsletter, Sentinel Event Alert.
As sentinel events are reported
to JCAHO, a sentinel event advisory group works to develop
goals that focus on system-wide
solutions in order to prevent subsequent events from occurring,
thereby enhancing the quality of
care received within JCAHOaccredited institutions.

Streptokinase and Urokinase
• Formulary Update

As with JCAHO standards, accredited organizations are evalu-

ated for continuous compliance
with the specific requirements associated with NPSGs. The following goals and requirements are
those pertaining to hospitals only.
New goals and requirements are
italicized.
Goal 1: Improve the accuracy of
patient identification.
• Requirement 1A: Use at least
2 patient identifiers when
administering medications or
blood products, when taking
blood samples and other specimens, or when providing any
other treatments or procedures.
Acceptable identifiers may
be the individual’s name,
an assigned identification number, telephone number, photograph, or other person-specific
identifier.
Goal 2: Improve the effectiveness
of communication among all
caregivers.
• Requirement 2A: For verbal
or telephone orders or for telephonic reporting of critical test
results, verify the complete order or test result by having the
person receiving the order or
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test result read back the complete order or test result. Whenever possible, the receiver of the
order should write down the
complete order or test result or
enter it into a computer, and
then read it back to confirm
with the individual who gave
the order or test result.
• Requirement 2B: Standardize
a list of abbreviations, acronyms, and symbols that are not
to be used in the organization.
A list is provided in MUSC-MC
policy C-21, Use of Abbreviations.
• Requirement 2C: Measure,
assess, and take action to improve the timeliness of reporting and the timeliness of receipt
by the responsible licensed
caregiver of critical test results
and values.
• Requirement 2E: Implement
a standardized approach to
“hand off” communications,
including an opportunity to ask
and respond to questions. Hand
offs include up-to-date information regarding the patient’s
care, treatment and services,
condition, and any recent or
anticipated changes. Interruptions during hand offs should be
limited to minimize the possibility that information would
fail to be conveyed or would
be forgotten.

• Requirement 3C: Identify
and annually review a list of
look-alike, sound-alike medications used in the organization, and take action to prevent
errors involving the interchange of these agents. The
specific
medications
and
strategies chosen at MUSC are
described on pages 3 and 4.
• Requirement 3D: Label all
medication containers (eg, syringes, medicine cups, basins),
or other solutions on and
off the sterile field in perioperative and other procedural settings.
Goal 7: Reduce the risk of
healthcare-associated infections.
• Requirement 7A: Comply
with current Centers for Disease Control and Prevention
hand hygiene guidelines. This
information is posted at
www.cdc.gov/handhygiene/.
• Requirement 7B: Manage all
identified cases of unanticipated death or major permanent loss of function related to
a healthcare-associated infection as sentinel events. These
unanticipated deaths and injuries meet the definition of a
sentinel event and are required
to undergo a root cause analysis.

Goal 3: Improve the safety of using medications.

Goal 8: Accurately and completely reconcile medications
across the continuum of care.

• Requirement 3B: Standardize
and limit the number of drug
concentrations available. This
can be interpreted as eliminating use of the “rule of six” in
the Children’s Hospital.

• Requirement 8A: Implement
a process for obtaining and
documenting a complete list of
the patient’s current medications upon admission to the
organization.

• Requirement 8B: A complete
list of the patient’s medications
is communicated to the next
provider of service whenever a
patient is referred or transferred
to another setting, service, practitioner, or level of care within
or outside the organization.
Goal 9: Reduce the risk of patient
harm resulting from falls.
• Requirement 9B: Implement a
fall reduction program and
evaluate the effectiveness of the
program.
Further information on NPSGs
and implementation expectations
is posted at www.jcaho.org.
In an effort to improve our compliance, Quality Management is
currently posting the NPSGs
throughout the organization and
drafting posters to raise awareness
regarding other JCAHO requirements such look-alike, soundalike medications and the universal protocol for preventing wrong
site, wrong procedure, or wrong
person surgery.

Look-alike, Sound-alike
Medications at MUSC
By: Katie Namtu
Pharmacy Practice Resident
In 2001, the Joint Commission on
Accreditation of Healthcare Organizations (JCAHO) published a
Sentinel Event Alert on look-alike,
sound-alike medications (LASAs).
Since then, this initiative has been
added to the 2006 National Patient
Safety Goals (NPSGs). Based on
the goals, an organization must
choose a minimum of 10 look-
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alike, sound-alike
combinations.
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medication

The Medication Safety Team has
chosen 10 medication combinations that are potentially problematic (see page 4). Errors associated with these medications can
lead to serious adverse drug reactions (ADRs). In addition, strategies were developed to prevent
medications errors due to lookalike, sound-alike medications and
are as follows.
• Tall man lettering on preprinted
order forms, computerized
screens, and medication labels
• Storage segregation in the
pharmacies and AcuDose-Rx®
cabinets
• Alert
stickers
posted
in
the pharmacy areas and AcuDose-Rx® cabinets
• Specific labeling of the medication pockets in the AcuDoseRx® cabinets
• Alternate distribution and storage systems for insulin products
• Staff awareness of the differences between conventional and
lipid-based formulations

MED•U•WAY
Conference to Focus on
Sickle Cell Disease
The next MED•U•WAY
conference will focus on the
practical management of sickle
cell disease. The program will be
held on Thursday, May 18, 2006,
at 12:00 PM, in 2 West
Amphitheater.
The featured speakers will be
Sherron Jackson, MD, Division of
Pediatric Hematology/Oncology,
N. Robert Axon, MD, Division of

General Internal Medicine and
Geriatrics; Dominic Ragucci,
PharmD, BCPS, Department of
Pharmacy Services; and Brenda
Gumm-Carey, RN, Nurse Case
Manager, Clinical Effectiveness.
Attendees will receive 1 credit
hour of continuing education,
and lunch is provided.

Discontinuation of
Streptokinase and
Urokinase
Streptokinase (Streptase®) and
urokinase (Abbokinase®) have
been discontinued by their
manufacturers. Currently, the
clinical pharmacy staff is working with the primary users of
these medications to determine
appropriate alternatives. If you
have any additional questions
regarding this issue, please contact Heather Kokko, PharmD, at
kokko@musc.edu.

Formulary Update
The Pharmacy and Therapeutics
Committee recently approved
the following changes:
Additions:
Effective April 17, 2006
Rifaximin (Xifaxan®)
200-mg tablet
®

Moxifloxacin (Avelox )
400-mg tablet and 400-mg/mL
intravenous solution
Added with restriction:
Effective date pending
17-alpha hydroxyprogesterone
caproate will be restricted for
use in women with a history of
spontaneous preterm birth, sin-

gleton gestation, and who are
receiving prenatal care.
Change in restriction:
Effective April 17, 2006
Nesiritide (Natrecor®) is restricted for prescribing by cardiology or cardiothoracic surgery
attending physicians and fellows
for patients with documented
acutely decompensated heart
failure.
Line extensions:
Effective April 17, 2006
Lorazepam (various)
0.5-mg/mL extemporaneously
prepared oral suspension
Trimethobenzamide (Tigan®)
300-mg capsule
Kaletra®
200-mg/50-mg tablet
Olanzapine (Zyprexa®)
5-, 15-, and 20-mg tablet
Pregestimil® RTF Formula
3-ounce bottle
Deletions:
Effective April 17, 2006
Gatifloxacin (Tequin®)
200- and 400-mg tablet, 200and 400-mg/mL intravenous
solution
Lorazepam (various)
2-mg/mL oral suspension
Trimethobenzamide (Tigan®)
250-mg capsule
Kaletra®
133.3-mg/33.3-mg capsule
Thiethylperazine (Torecan®)
5-mg/mL injection
Humulin® 50/50
100-units/mL vial
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PROBLEMATIC MEDICATION NAMES

POTENTIAL ERRORS AND CONSEQUENCES

Chemotherapeutic Agents
Doses for carboplatin generally exceed the maximum safe
dose of cisplatin. Severe toxicity and death have been associated with accidental cisplatin administration.
Confusion between these medications may result in serious
adverse outcomes since they have different dosing recommendations and are used for the treatment of different cancers.
Confusion between these medications may result in serious
adverse outcomes since they have different dosing recommendations and are used for the treatment of different cancers.
Confusion between these medications may result in serious
adverse outcomes since they have different dosing recommendations and are used for the treatment of different cancers.
Due to name similarity, fatal errors have occurred when patients were given vincristine at a higher vinblastine dose.

CISplatin (Platinol®)
CARBOplatin (Paraplatin®)
PACLItaxel (Taxol®)
DOCEtaxel (Taxotere®)
DACTINOmycin (Cosmegen®)
DAUNOrubicin (Cerubidine®)
DOXOrubicin (Adriamycin®, Rubex®)
DAUNOrubicin (Cerubidine®)
VinBLAStine (Velban®)
VinCRIStine (Oncovin®)

Conventional versus Liposomal Chemotherapeutic Agents
DOXOrubicin, CONVENTIONAL (Adriamycin®, Rubex®)
DOXOrubicin LIPOSOMAL (Doxil®)
DAUNOrubicin, CONVENTIONAL (Cerubidine®)
DAUNOrubicin LIPOSOMAL (Daunoxome®)
PACLItaxel, CONVENTIONAL (Onxol™, Taxol®)
PACLItaxel, LIPOSOMAL (Abraxane™)

These products are not interchangeable. Lipid-based formulation dosing guidelines differ significantly from conventional
dosing. Accidental administration of the liposomal product,
instead of the intended conventional product, has resulted in
death.

Cytarabine, CONVENTIONAL (Cytosar-U®)
Cytarabine, LIPOSOMAL (DepoCyt™)

Opioid Analgesics
CONVENTIONAL morphine oral liquid (MSIR®)
Morphine CONCENTRATED liquid (Roxanol®)
®

HYDROmorphONE injection (Dilaudid )
MorphINE injection (various)

Concentrated (20 mg/mL) morphine has been confused with
conventional strengths (eg, 2 mg/mL and 4 mg/mL).
These products are not interchangeable. Fatal errors have occurred when hydromorphone was confused with morphine. For
equianalgesic dosing information, please refer to the opioid
analgesic comparison chart at http://www.musc.edu/
pharmacyservices/medusepol/opioidanalgesicfinal.pdf.

Insulin Products
Novolin R
Novolin NPH
Novolin 70/30
®
Lispro (Humalog®) - NF
Aspart (Novolog )
Novolog 70/30
Humalog 75/25 - NF
Glargine (Lantus®)
Humulin® R U-500

Similar names, strengths, and concentration ratios have led to
numerous medication errors. For more information regarding
the insulin products, please refer to the insulin products comparison chart at http://www.musc.edu/pharmacyservices/
medusepol/InsulinComparisonChart.pdf.

Amphotericin
Amphotericin B desoxycholate (Amphocin®, Fungizone®)
Amphotericin B cholesteryl sulfate complex (Amphotec®) – NF
Amphotericin B liposomal (Ambisome®)
Amphotericin B lipid complex (Abelcet®) -NF

These products are not interchangeable. Doses of the lipidbased products are higher and vary from product to product.
Confusion between these products has resulted in episodes of
severe and sometimes fatal outcomes.

Other Medications
LaMOTRIgine (Lamictal®)
LaMIVUdine (Epivir®)
Bupropion (Wellbutrin® SR)
Bupropion (Wellbutrin® XL) - NF
‡

Nonformulary (NF) products

These medications are from different medication classes. Patients erroneously receiving one of these medications could
experience adverse outcomes and would not receive the intended treatment for their illness.
These formulations are not interchangeable. The sustained
release (SR) product is typically dosed twice daily, and the
extended release (XL) formulation is dosed once daily.

